Lisata Therapeutics has acquired clinical-stage biotech Marea Therapeutics in an all-stock transaction, according to a source report dated September 18, 2026. The purchase amount was not disclosed in the sources.
The same source states that Lisata secured a concurrent $225 million private placement. That capital provides operational runway into 2028, primary funding for Marea's lead ANGPTL4-targeting Phase 2b asset MAR001/005 in severe hypertriglyceridemia, and support for MAR002 in acromegaly.
The source describes the acquisition as strategic and says it pivots the combined company's focus toward first-in-class cardioendocrine therapies.